國立虎尾科技大學 |

Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy = A MASCC Book /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy/ edited by Maryam Lustberg, Charles Loprinzi.
其他題名:	A MASCC Book /
其他作者:	Loprinzi, Charles.
面頁冊數:	VIII, 263 p. 11 illus., 9 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Cancer Research. -
電子資源:	https://doi.org/10.1007/978-3-030-78663-2
ISBN:	9783030786632

Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy = A MASCC Book /
Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced NeuropathyA MASCC Book /[electronic resource] :edited by Maryam Lustberg, Charles Loprinzi. - 1st ed. 2021. - VIII, 263 p. 11 illus., 9 illus. in color.online resource.

Natural History of Chemotherapy Induced Neuropathy -- Predisposing factors for the development of CIPN -- Evaluation of Chemotherapy-Induced Peripheral Neuropathy -- Preventive Strategies for Chemotherapy-in-duced Peripheral Neuropathy -- Prevention of CIPN – Current Clinical Data and Future Directions -- Treatment of established CIPN: basic science and animal models -- Pharmacological Treatment of Established CIPN -- Systematic review of exercise for prevention and management of chemotherapy-induced peripheral neuropathy -- Clinical and practical recommendations in the use of exercise, physical therapy, and occupational therapy for chemotherapy-induced peripheral neuropathy -- Natural course of neurotoxicity after immune checkpoint inhibitor (ICI) exposure -- Ants and Needles and Pins – Living with Neuropathy.

This book comprehensively examines chemotherapy-induced peripheral neuropathy (CIPN), a common dose-limiting condition that negatively affects both the quality of life of cancer patients and disease outcomes. CIPN remains a challenging area for both clinical care and research, as there are multiple unresolved issues. Written by leading international experts, the book discusses the natural history of CIPN, the latest predictors of toxicity, instruments for evaluating symptoms, and prevention/therapeutic strategies, as well as patients’ experiences of this common clinical syndrome. Lastly it highlights avenues for future research to enhance our understanding of CIPN. Providing essential information on the management of CIPN and the latest research in the field, this book is a valuable resource for researchers and healthcare providers working with patients with various malignant diseases.

ISBN: 9783030786632

Standard No.: 10.1007/978-3-030-78663-2doiSubjects--Topical Terms:

668358
Cancer Research.

LC Class. No.: RC261-271

Dewey Class. No.: 614.5999

Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy = A MASCC Book /
LDR:03165nam a22003975i 4500 001 1055825
003 DE-He213
005 20211007125922.0
007 cr nn 008mamaa
008 220103s2021 sz | s |||| 0|eng d
020 $a 9783030786632 $9 978-3-030-78663-2
024 7 $a 10.1007/978-3-030-78663-2 $2 doi
035 $a 978-3-030-78663-2
050 4 $a RC261-271
072 7 $a MJCL $2 bicssc
072 7 $a MED062000 $2 bisacsh
072 7 $a MJCL $2 thema
082 0 4 $a 614.5999 $2 23
245 1 0 $a Diagnosis, Management and Emerging Strategies for Chemotherapy-Induced Neuropathy $h [electronic resource] : $b A MASCC Book / $c edited by Maryam Lustberg, Charles Loprinzi.
250 $a 1st ed. 2021.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2021.
300 $a VIII, 263 p. 11 illus., 9 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
505 0 $a Natural History of Chemotherapy Induced Neuropathy -- Predisposing factors for the development of CIPN -- Evaluation of Chemotherapy-Induced Peripheral Neuropathy -- Preventive Strategies for Chemotherapy-in-duced Peripheral Neuropathy -- Prevention of CIPN – Current Clinical Data and Future Directions -- Treatment of established CIPN: basic science and animal models -- Pharmacological Treatment of Established CIPN -- Systematic review of exercise for prevention and management of chemotherapy-induced peripheral neuropathy -- Clinical and practical recommendations in the use of exercise, physical therapy, and occupational therapy for chemotherapy-induced peripheral neuropathy -- Natural course of neurotoxicity after immune checkpoint inhibitor (ICI) exposure -- Ants and Needles and Pins – Living with Neuropathy.
520 $a This book comprehensively examines chemotherapy-induced peripheral neuropathy (CIPN), a common dose-limiting condition that negatively affects both the quality of life of cancer patients and disease outcomes. CIPN remains a challenging area for both clinical care and research, as there are multiple unresolved issues. Written by leading international experts, the book discusses the natural history of CIPN, the latest predictors of toxicity, instruments for evaluating symptoms, and prevention/therapeutic strategies, as well as patients’ experiences of this common clinical syndrome. Lastly it highlights avenues for future research to enhance our understanding of CIPN. Providing essential information on the management of CIPN and the latest research in the field, this book is a valuable resource for researchers and healthcare providers working with patients with various malignant diseases.
650 1 4 $a Cancer Research. $3 668358
650 0 $a Physiology. $3 673386
650 0 $a Neurosciences. $3 593561
650 0 $a Cancer research. $3 1253664
700 1 $a Loprinzi, Charles. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1361109
700 1 $a Lustberg, Maryam. $e editor. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1361108
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783030786625
776 0 8 $i Printed edition: $z 9783030786649
776 0 8 $i Printed edition: $z 9783030786656
856 4 0 $u https://doi.org/10.1007/978-3-030-78663-2
912 $a ZDB-2-SBL
912 $a ZDB-2-SXB
950 $a Biomedical and Life Sciences (SpringerNature-11642)
950 $a Biomedical and Life Sciences (R0) (SpringerNature-43708)